← All Tempest Therapeutics, INC filings

Tempest Therapeutics, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
TPST
Tempest Therapeutics, INC
10-K: Tempest pivots to dual CAR‑T; cash runway tight
Tempest Therapeutics closed a share-funded CAR‑T asset deal, reported striking early multiple myeloma data, and outlined 2026 milestones, but flagged a going‑concern risk with just $7.7M in cash and reliance on an uncertain funding commitment.
NASDAQ
TPST
Tempest Therapeutics, INC
10-K/A: Tempest Therapeutics Files Amendment No. 1 to Form 10-K, Updating Executive and Financial Certifications
Tempest Therapeutics files an amendment to its annual report on Form 10-K to include required information on directors, executive officers, corporate governance, and updated certifications.
NASDAQ
TPST
Tempest Therapeutics, INC
10-K: Tempest Therapeutics Reports Positive Clinical Trial Progress and Outlines Future Strategy in 2024 10-K Filing
Tempest Therapeutics highlights positive clinical trial results for amezalpat and TPST-1495, alongside strategic plans for pipeline expansion and business development in its 2024 10-K filing.
NASDAQ
TPST
Tempest Therapeutics, INC
10-K: Tempest Therapeutics Outlines Securities and Rights Plan in 10-K Filing
Tempest Therapeutics details its common and preferred stock structure, including a recently adopted stockholder rights plan, in its annual 10-K filing.